作者:Bini Mathew、Judith V. Hobrath、Michele C. Connelly、R. Kiplin Guy、Robert C. Reynolds
DOI:10.1016/j.bmcl.2017.09.022
日期:2017.10
Sulindac is a non-steroidal anti-inflammatory drug (NSAID) that has shown significant anticancer activity. Sulindac sulfide amide (1) possessing greatly reduced COX-related inhibition relative to sulindac displayed in vivo antitumor activity that was comparable to sulindac in a human colon tumor xenograft model. Inspired by these observations, a panel of diverse sulindac amide derivatives have been
舒林酸是一种非甾体抗炎药(NSAID),已显示出显着的抗癌活性。相对于舒林酸,舒林酸硫化物酰胺(1)具有大大降低的COX相关抑制作用,在人结肠肿瘤异种移植模型中具有与舒林酸相当的体内抗肿瘤活性。受这些观察结果的启发,已经合成了一组不同的舒林酸酰胺衍生物,并针对三种癌细胞系(前列腺癌,结肠癌和乳腺癌)探测了它们的活性。鉴定出一种中性类似物化合物79具有相对于铅1相当的效力,并且对一组淋巴细胞性白血病细胞系具有活性。相对于父系,几个新系列也表现出良好的活动性(1),包括五个类似的类似物,它们也具有针对急性淋巴细胞白血病细胞的纳摩尔抑制力。鉴定出的几种新的类似物可作为抗癌药物的潜在候选者,以进行进一步的开发。